VRTX · Vertex Pharmaceuticals Inc / Ma
$505.75
-10.69 (-2.07%)
At close · Aug 14
Market Cap
$133.25B
Shares
253.46M
Vertex Pharmaceuticals Inc Earnings Call Transcripts
Every quarterly earnings call for Vertex Pharmaceuticals Inc (VRTX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲17.7%
$2.33B
$930.50M
'22 Q3
22-10-27
▲11.1%
$2.30B
$818.90M
'22 Q4
23-02-07
▲13.2%
$2.37B
$699.80M
'23 Q1
23-05-01
▲13.5%
$2.49B
$915.70M
'23 Q2
23-08-01
▲6.4%
$2.48B
$1.04B
'23 Q3
23-11-06
▲9.3%
$2.52B
$968.80M
'23 Q4
24-02-05
▲13.3%
$2.69B
$1.10B
'24 Q1
24-05-06
▲6.1%
$2.65B
−$3.59B
'24 Q2
24-08-01
▲11.6%
$2.77B
$1.05B
'24 Q3
24-11-04
▲15.7%
$2.91B
$913.00M
'24 Q4
25-02-10
▲3%
$2.77B
$646.30M
'25 Q1
25-05-05
▲12.1%
$2.96B
$1.03B
'25 Q2
25-08-04
▲11%
$3.08B
$1.08B
'25 Q3
25-11-03
▲9.5%
$3.19B
$1.19B
'25 Q4
26-02-12
▲7.8%
$2.99B
$1.03B
'26 Q1
26-05-04
LATEST
▲12.5%
$3.33B
$1.10B
'26 Q2
26-08-03
Earnings call
FY26 · Q2
2026-08-03
Vertex Pharmaceuticals Q2 2026 Conference Call
Confident tone
Cystic Fibrosis Franchise
DM1 Program
Regulatory Milestones
Revenue
$3.33B
▲ 12.5% YoY Diluted EPS
$4.31
▲ 8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-07-06
Vertex Pharmaceuticals Acquisition of Crinetics Pharmaceuticals Conference Call
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-10
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-29
Bernstein’s 42nd Annual Strategic Decisions Conference (SDC)
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-04
Vertex Pharmaceuticals Inc / Ma Q1 FY2026 Earnings Call
Confident tone
Renal franchise / POVI (povetacicept)
Cystic Fibrosis franchise (Trikafta/Aliftrek)
Inaxaplin AMKD program
Revenue
$2.99B
▲ 7.8% YoY Diluted EPS
$4.02
▲ 61.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-11
Barclays 28th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-12
Vertex Pharmaceuticals Inc / Ma Q4 FY2025 Earnings Call
Confident tone
Renal franchise and Povetacicept (POVI)
Clinical trial readouts and DSMB / Rainier study
Financial guidance and 2026 outlook
Revenue
$3.19B*
▲ 9.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Vertex Pharmaceuticals Inc / Ma Q3 FY2025 Earnings Call
Confident tone
Cystic Fibrosis Franchise and ALYFTREK Uptake
Pain Portfolio (JOURNAVX in Acute and Neuropathic Pain)
Renal Pipeline (Povetacicept, Inaxaplin, VX-407)
Revenue
$3.08B
▲ 11% YoY Diluted EPS
$4.20
▲ 4.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Vertex Pharmaceuticals Inc / Ma Q2 FY2025 Earnings Call
Confident tone
JOURNAVX (acute pain) launch and access
CF franchise and ALYFTREK launch
CASGEVY cell therapy momentum
Revenue
$2.96B
▲ 12.1% YoY Diluted EPS
$3.99
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Vertex Pharmaceuticals Inc / Ma Q1 FY2025 Earnings Call
Revenue
$2.77B
▲ 3% YoY Diluted EPS
$2.49
▼ 40.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-10
Vertex Pharmaceuticals Inc / Ma Q4 FY2024 Earnings Call
Confident tone
JOURNAVX (suzetrigine) launch in acute pain
Cystic Fibrosis franchise performance and ALYFTREK launch
CASGEVY launch in sickle cell disease and beta thalassemia
Revenue
$2.91B*
▲ 15.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Vertex Pharmaceuticals Inc / Ma Q3 FY2024 Earnings Call
Confident tone
Suzetrigine (VX-548) in acute pain and access
CASGEVY launch in sickle cell disease and beta thalassemia
Povetacicept in IgA nephropathy and broader autoimmune
Revenue
$2.77B
▲ 11.6% YoY Diluted EPS
$4.01
▲ 1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Vertex Pharmaceuticals Inc / Ma Q2 FY2024 Earnings Call
Confident tone
Suzetrigine acute pain launch
Cystic Fibrosis (Vanzacaftor Triple launch)
CASGEVI launch (sickle cell / beta-thalassemia)
Revenue
$2.65B
▲ 6.1% YoY Diluted EPS
$-13.92
▼ 495.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Vertex Pharmaceuticals Inc / Ma Q1 FY2024 Earnings Call
Confident tone
Suzetrigine acute pain NDA and launch readiness
CASGEVY launch in sickle cell disease and beta thalassemia
Alpine Immune Sciences acquisition and povetacicept
Revenue
$2.69B
▲ 13.3% YoY Diluted EPS
$4.21
▲ 56.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-05
Vertex Pharmaceuticals Inc / Ma Q4 FY2023 Earnings Call
Confident tone
Cystic Fibrosis / vanzacaftor triple (vanza)
Acute pain program VX-548
Pipeline expansion into new disease areas
Revenue
$2.52B*
▲ 9.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Vertex Pharmaceuticals Inc / Ma Q3 FY2023 Earnings Call
Revenue
$2.48B
▲ 6.4% YoY Diluted EPS
$3.97
▲ 10.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Vertex Pharmaceuticals Inc / Ma Q2 FY2023 Earnings Call
Revenue
$2.49B
▲ 13.5% YoY Diluted EPS
$3.52
▲ 12.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-01
Vertex Pharmaceuticals Inc / Ma Q1 FY2023 Earnings Call
Revenue
$2.37B
▲ 13.2% YoY Diluted EPS
$2.69
▼ 9.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-07
Vertex Pharmaceuticals Inc / Ma Q4 FY2022 Earnings Call
Revenue
$2.30B*
▲ 11.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Vertex Pharmaceuticals Inc / Ma Q3 FY2022 Earnings Call
Revenue
$2.33B
▲ 17.7% YoY Diluted EPS
$3.59
▲ 9.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Vertex Pharmaceuticals Inc / Ma Q2 FY2022 Earnings Call
Revenue
$2.20B
▲ 22.5% YoY Diluted EPS
$3.13
▲ 1103.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Vertex Pharmaceuticals Inc / Ma Q1 FY2022 Earnings Call
Revenue
$2.10B
▲ 21.6% YoY Diluted EPS
$2.96
▲ 18.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-26
Vertex Pharmaceuticals Inc / Ma Q4 FY2021 Earnings Call
Revenue
$2.07B*
▲ 27.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Vertex Pharmaceuticals Inc / Ma Q3 FY2021 Earnings Call
Revenue
$1.98B
▲ 29% YoY Diluted EPS
$3.28
▲ 29.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Vertex Pharmaceuticals Inc / Ma Q2 FY2021 Earnings Call
Revenue
$1.79B
▲ 17.6% YoY Diluted EPS
$0.26
▼ 91.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Vertex Pharmaceuticals Inc / Ma Q1 FY2021 Earnings Call
Revenue
$1.72B
▲ 13.8% YoY Diluted EPS
$2.49
▲ 8.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-01
Vertex Pharmaceuticals Inc / Ma Q4 FY2020 Earnings Call
Revenue
$1.63B
▲ 15.2% YoY Diluted EPS
$2.30
▲ 3.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Vertex Pharmaceuticals Inc / Ma Q3 FY2020 Earnings Call
Revenue
$1.54B
▲ 62% YoY Diluted EPS
$2.53
▲ 1050% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Vertex Pharmaceuticals Inc / Ma Q2 FY2020 Earnings Call
Revenue
$1.52B
▲ 62% YoY Diluted EPS
$3.18
▲ 208.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-29
Vertex Pharmaceuticals Inc / Ma Q1 FY2020 Earnings Call
Revenue
$1.52B
▲ 76.5% YoY Diluted EPS
$2.29
▲ 122.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-30
Vertex Pharmaceuticals Inc / Ma Q4 FY2019 Earnings Call
Revenue
$1.41B
▲ 62.4% YoY Diluted EPS
$2.23
▼ 62.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–31 of 31 earnings calls
Key facts
CIK
875320
CUSIP
92532F100
13F (30d)
1575 filings
1529 filers
Visit website
Investor relations